Literature DB >> 1801680

Catecholamines in experimentally growth-retarded rat fetus.

T Hiraoka1, T Kudo, Y Kishimoto.   

Abstract

This study was designed to evaluate the sympathoadrenal system in rat IUGR fetuses prepared by the Wigglesworth method. Samples were obtained on day 20 of gestation. In the amniotic fluid, concentrations of norepinephrine (NE) and particularly epinephrine (E) were significantly higher in IUGR fetuses than in normally developed fetuses (NE: p less than 0.05, E: p less than 0.01). L-Dopa and three catecholamines in the adrenal glands were decreased in IUGR fetuses. The mol ratios (L-dopa: dopamine: NE: E) were 1: 4: 35: 63 in IUGR fetuses and 1: 5: 39: 87 in normal fetuses. The ratio for epinephrine to L-dopa was significantly lower in IUGR fetuses (p less than 0.05). Adrenal phenylethanolamine-N-methyltransferase activities showed no difference between the two groups. From these results, adrenal epinephrine synthesis in IUGR fetuses was thought to be normal. Because of the depletion of adrenal epinephrine in IUGR fetuses, the plasma epinephrine concentrations were significantly lower after acute hemorrhagic shock (p less than 0.01). However, the plasma concentrations of dopamine and norepinephrine were significantly higher (dopamine: p less than 0.01, NE: p less than 0.001) in IUGR fetuses. These findings suggest that the hypersecretion of adrenal epinephrine is a protective response to chronic stress and the decrease of adrenal epinephrine may be a causative factor for the reduced reserves in the defense mechanism of IUGR fetuses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801680     DOI: 10.1111/j.1447-0756.1991.tb00284.x

Source DB:  PubMed          Journal:  Asia Oceania J Obstet Gynaecol        ISSN: 0389-2328


  15 in total

Review 1.  Intrauterine growth restriction: fetal programming of hypertension and kidney disease.

Authors:  Norma B Ojeda; Daniela Grigore; Barbara T Alexander
Journal:  Adv Chronic Kidney Dis       Date:  2008-04       Impact factor: 3.620

Review 2.  Sex differences in the fetal programming of hypertension.

Authors:  Daniela Grigore; Norma B Ojeda; Barbara T Alexander
Journal:  Gend Med       Date:  2008

Review 3.  Developmental programming of hypertension: insight from animal models of nutritional manipulation.

Authors:  Norma B Ojeda; Daniela Grigore; Barbara T Alexander
Journal:  Hypertension       Date:  2008-05-12       Impact factor: 10.190

4.  Role of fetal programming in the development of hypertension.

Authors:  Norma B Ojeda; Daniela Grigore; Barbara T Alexander
Journal:  Future Cardiol       Date:  2008-03

Review 5.  Fetal programming and cardiovascular pathology.

Authors:  Barbara T Alexander; John Henry Dasinger; Suttira Intapad
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

Review 6.  Sex differences in the developmental origins of cardiovascular disease.

Authors:  Suttira Intapad; Norma B Ojeda; John Henry Dasinger; Barbara T Alexander
Journal:  Physiology (Bethesda)       Date:  2014-03

Review 7.  Fetal programming and early identification of newborns at high risk of free radical-mediated diseases.

Authors:  Serafina Perrone; Antonino Santacroce; Anna Picardi; Giuseppe Buonocore
Journal:  World J Clin Pediatr       Date:  2016-05-08

8.  Early renal denervation prevents development of hypertension in growth-restricted offspring.

Authors:  Norma B Ojeda; W Russell Johnson; Terry M Dwyer; Barbara T Alexander
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-11       Impact factor: 2.557

9.  Adrenal Demedullation and Oxygen Supplementation Independently Increase Glucose-Stimulated Insulin Concentrations in Fetal Sheep With Intrauterine Growth Restriction.

Authors:  Antoni R Macko; Dustin T Yates; Xiaochuan Chen; Leslie A Shelton; Amy C Kelly; Melissa A Davis; Leticia E Camacho; Miranda J Anderson; Sean W Limesand
Journal:  Endocrinology       Date:  2016-03-03       Impact factor: 4.736

Review 10.  Developmental programming and hypertension.

Authors:  Anne Monique Nuyt; Barbara T Alexander
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-03       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.